Unknown

Dataset Information

Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials.


ABSTRACT: Glioblastoma (GB), a prevalent and highly malignant primary brain tumour with a very high mortality rate due to its resistance to conventional therapies and invasive nature, resulting in 5-year survival rates of only 4-17%. Despite recent advancements in cancer management, the survival rates for GB patients have not significantly improved over the last 10-20 years. Consequently, there exists a critical unmet need for innovative therapies. One promising approach for GB is Targeted Alpha Therapy (TAT), which aims to selectively deliver potentially therapeutic radiation doses to malignant cells and the tumour microenvironment while minimising radiation exposure to surrounding normal tissue with or without conventional external beam radiation. This approach has shown promise in both pre-clinic

SUBMITTER: Sabri ME 

PROVIDER: S-EPMC11230998 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature